Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (241-250 of 464) with videos related to

Pageof 47
Sort By:
Gastroenterology|July 8, 2019
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's DiseaseKatherine Li, Joshua R Friedman, Daphne Chan, et al.
Gastroenterology|February 8, 2002
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's diseaseWilliam J Sandborn, Brian G Feagan, Stephen B Hanauer, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|May 19, 2022
Development and Validation of a Digital Analysis Method to Quantify CD3-immunostained T Lymphocytes in Whole Slide Images of Crohn's Disease BiopsiesPavine Lefèvre, Leonardo Guizzetti, Trevor D McKee, et al.
Lancet (London, England)|June 6, 2002
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialStephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, et al.
Gastroenterology|February 6, 2004
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's diseasePaul Rutgeerts, Brian G Feagan, Gary R Lichtenstein, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2019
Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative ColitisChristopher Ma, William J Sandborn, Geert R D'Haens, et al.
Journal of Crohn'S & Colitis|January 13, 2021
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE StudyWilliam J Sandborn, Brian G Feagan, Stephen Hanauer, et al.
Crohn'S & Colitis 360|February 3, 2025
Certolizumab Pegol Treatment in Patients With Crohn's Disease: Final Safety Data From the SECURE RegistryGary R Lichtenstein, Scott D Lee, Brian G Feagan, et al.
The American Journal of Gastroenterology|July 20, 2018
Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive ReportGary R Lichtenstein, Brian G Feagan, Uma Mahadevan, et al.
Gut|December 10, 2015
Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohortCorinne Gower-Rousseau, Hélène Sarter, Guillaume Savoye, et al.
Pageof 47

Showing results (241-250 of 464) with videos related to

Sort By:
Pageof 47
Gastroenterology|July 8, 2019
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's DiseaseKatherine Li, Joshua R Friedman, Daphne Chan, et al.
Gastroenterology|February 8, 2002
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's diseaseWilliam J Sandborn, Brian G Feagan, Stephen B Hanauer, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|May 19, 2022
Development and Validation of a Digital Analysis Method to Quantify CD3-immunostained T Lymphocytes in Whole Slide Images of Crohn's Disease BiopsiesPavine Lefèvre, Leonardo Guizzetti, Trevor D McKee, et al.
Lancet (London, England)|June 6, 2002
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialStephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, et al.
Gastroenterology|February 6, 2004
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's diseasePaul Rutgeerts, Brian G Feagan, Gary R Lichtenstein, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2019
Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative ColitisChristopher Ma, William J Sandborn, Geert R D'Haens, et al.
Journal of Crohn'S & Colitis|January 13, 2021
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE StudyWilliam J Sandborn, Brian G Feagan, Stephen Hanauer, et al.
Crohn'S & Colitis 360|February 3, 2025
Certolizumab Pegol Treatment in Patients With Crohn's Disease: Final Safety Data From the SECURE RegistryGary R Lichtenstein, Scott D Lee, Brian G Feagan, et al.
The American Journal of Gastroenterology|July 20, 2018
Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive ReportGary R Lichtenstein, Brian G Feagan, Uma Mahadevan, et al.
Gut|December 10, 2015
Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohortCorinne Gower-Rousseau, Hélène Sarter, Guillaume Savoye, et al.
Pageof 47